References

  1. Lynparza (olaparib) Summary of Product Characteristics.
  2. Myriad. Myriad myChoice® HRD Technical Specifications. (2017).
  3. O'Connor, M. J. Targeting the DNA Damage Response in Cancer. Mol. Cell 60, 547 -560 (2015).
  4. Peng, G. et al. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat. Commun 5, 3361 (2014).
  5. Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I. & D'Andrea, A. D. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 5, 1137 -1154 (2015).
  6. Moschetta, M., George, A., Kaye, S. B. & Banerjee, S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann. Oncol. 27, 1449 -1455 (2016).
  7. Ray-Coquard, I. et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med 381, 2416 -2428 (2019).
  8. Genetic testing process. Myriad Genetics https://myriad.com/healthcare-professionals/about-genetic-testing/genetic-testing-process/.
  9. Capoluongo, E. et al. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Semin. Oncol. 44, 187 -197 (2017).
  10. Ledermann, J. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24 Suppl 6, vi24-32 (2013).
  11. Overview | Ovarian cancer: recognition and initial management | Guidance | NICE. https://www.nice.org.uk/Guidance/CG122.
  12. NHS England. National Cancer Drugs Fund list. https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/.

GB-23989 Date of preparation: March 2021